&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-11-09, 02:51

Io Therapeutics, Inc., announces presentation of data on its RAR gamma agonist compound IRX5010 demonstrating inhibition of tumor infiltrating myeloid derived suppressor cells, promotion of tumor infiltrating T-cells, and effective tumor growth inhibition
Monique Kunkel

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-10-29, 00:59

Berman Tabacco Announces Investigation of Evolv Technologies Holdings, Inc. (EVLV, EVLVW) Concerning Accounting Practices
Basil Slack

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-10-03, 22:18

Dark Horse Consulting Group Acquires BioTechLogic, Inc.
Tony Loman

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-09-18, 22:07

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical stage RXR agonist for treatment of normal aging-related neurodegeneration, at the FASEB Science Research Conference on Cellular and Molecular Mechanisms of Brai
Danny Gaylord

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-09-03, 20:25

Music Licensing, Inc. (OTC: SONG) Announces Acquisition of Royalty Rights to "Thank God I Got It" by Desiigner, Bolstering Its Diverse and Star-Studded Portfolio

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-08-22, 03:15

Olaplex Holdings, Inc. Announces Participation in the Barclays 17th Annual Global Consumer Staples Conference on September 4th
Tony Loman

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-08-15, 20:47

Matmerize, Inc., Introduces “ASKPOLY” – A Language Model Based Polymer Expert
Basil Slack

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-07-16, 20:26

Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis

Basil Slack

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-07-10, 07:00

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal

Jillian Pearce

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-07-09, 07:00

Io Therapeutics, Inc., announces presentation of data on induction of tumor growth inhibiting anti-cancer immune responses in multiple types of cancers by a IRX5010, a novel retinoic acid nuclear receptor agonist compound
Dora Legere

Popular Posts